OClawVPS.com
ReCode Therapeutics
Edit

ReCode Therapeutics

https://recodetx.com/
Last activity: 06.12.2025
Active
Categories: BioTechCauseDeliveryFutureHealthTechInformationITPlatform
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. The Company’s diverse pipeline includes lead programs for cystic fibrosis (CF) caused by nonsense mutations, and primary ciliary dyskinesia (PCD). ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively. The Company is leveraging its lipid nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. For more information, visit www.recodetx.com or contact us at info@recodetx.com.
Followers
269
Mentions
40
Location: United States, Texas, Dallas
Employees: 51-200
Total raised: $420M
Founded date: 2015

Investors 8

Funding Rounds 3

DateSeriesAmountInvestors
19.09.2023Series B$260M-
22.10.2021Series B$80M-
30.03.2020Series A$80M-

Mentions in press and media 40

DateTitleDescription
29.09.2025ReCode Therapeutics Raises Over $29M in Additional FinancingReCode Therapeutics, a Menlo Park, CA-based clinical-stage genetic medicines company, raised over $29M in additional funding. Backers were undisclosed. It also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) an...
13.06.2025Signify Bio: $15 Million Raised For Creating Personalized MedicinesSignify Bio, which is a pioneering biotechnology company harnessing the human body for the production of in situ protein therapeutics, announced an oversubscribed $15 million initial financing. The funding round was led by Actium Group with...
19.11.2024ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation-
26.09.2024ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis-
21.02.2024ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis-
16.02.2024Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis-
15.02.2024Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis-
20.10.2023Self-driving cars roll out in Houston, Q3 VC funding recap, and more trending innovation newsEditor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup articles on InnovationMap included a roundup of VC funding from last quarter, finalists name...
17.10.2023$5M grant expands entrepreneurship opportunities at UHA $5 million gift from the Wayne Duddlesten Foundation will establish expanded opportunities for entrepreneurship at the University of Houston, according to an announcement from the college earlier this month. Known as the Wayne B. Duddlest...
09.10.2023New energy institute from UH and Shell will put Houston at the center of innovationTwo years ago, Texas’ failing electrical grid became a global sensation and the state was thrust into the spotlight of the developing energy crisis conversation. This past year, Russia’s invasion of Ukraine again brought the push for altern...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In